Overview

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice

Details

Lead Sponsor:

Bayer

Collaborator:

Janssen Research & Development, LLC

Treatments:

Rivaroxaban